TransMedics Group, Inc. 2025 Q4 - Results - Earnings Call Presentation

TransMedics Group reported Q4 2025 earnings with revenue of $160.76 million, surpassing estimates by $5.49 million and marking a 32.18% year-over-year growth. Earnings per share (EPS) fell short at $0.05, missing analyst expectations by $0.32, indicating profitability challenges despite strong revenue performance. The earnings call presentation included a slide deck outlining financial results and operational highlights, released alongside the company’s 10-K filing. The report reflects continued expansion in TransMedics’ organ transplant technology sector, though investor focus remains on narrowing the EPS gap. Seeking Alpha’s transcripts team published the earnings call details, part of their broader coverage of quarterly corporate financial disclosures.